The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Cleboril     4-amino-N-(1-benzyl-4- piperidyl)-5-chloro...

Synonyms: Cleboprida, Clebopride, Clebopridum, Cleboril (TN), SureCN25710, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Clebopride


Psychiatry related information on Clebopride


High impact information on Clebopride

  • These results indicate that clebopride acts on post ganglionic cholinergic neurons at D2 and alpha-2 receptors in this preparation to enhance enteric nervous system stimulated motility [7].
  • 7. Clebopride and Delagrange 2674 inhibited [3H]-FNM binding with similar potency in rat cerebellar and hippocampal membranes, suggesting they have no selectivity for BDZ1 and BDZ2 binding sites.(ABSTRACT TRUNCATED AT 250 WORDS)[8]
  • 2. Clebopride, Delagrange 2674, Delagrange 2335 and BRL 20627 displayed concentration-dependent displacement of [3H]-FNM with IC50 values of 73 nM, 132 nM, 7.7 microM and 5.9 microM, respectively [8].
  • 6. The pattern of binding of clebopride and Delagrange 2674 in these in vitro tests is similar to that found previously with partial agonists or antagonists at BDZ binding sites [8].
  • An analysis of the hypothalamic sites at which the substituted benzamides, metoclopramide and clebopride, act to facilitate gastric emptying was undertaken in the guinea-pig [9].

Chemical compound and disease context of Clebopride


Biological context of Clebopride


Anatomical context of Clebopride


Associations of Clebopride with other chemical compounds


Gene context of Clebopride

  • When 5 mg of bromocriptine were given before clebopride, the PRL response was completely abolished as compared with the control experiment (P < 0.001) [10].
  • Climbing behaviour induced by NPA (2.5 mg/kg) could be antagonised by SCH23390 but not by clebopride, however climbing behaviour induced by a low dose of NPA (0.06 mg/kg) plus SKF38393 could be blocked by both D-1 and D-2 receptor antagonists [23].
  • Potentiation of the gastric antisecretory activity of histamine H2-receptor antagonists by clebopride [24].

Analytical, diagnostic and therapeutic context of Clebopride


  1. Transient dyskinesia induced by clebopride. Martínez-Martín, P. Mov. Disord. (1993) [Pubmed]
  2. Parkinsonian syndrome after long-term treatment with clebopride. Montagna, P., Gabellini, A.S., Monari, L., Lugaresi, E. Mov. Disord. (1992) [Pubmed]
  3. A double-blind comparison of clebopride and placebo in dyspepsia secondary to delayed gastric emptying. Bavestrello, L., Caimi, L., Barbera, A. Clinical therapeutics. (1985) [Pubmed]
  4. Progressive supranuclear palsy syndrome induced by clebopride. Campdelacreu, J., Kumru, H., Tolosa, E., Valls-Solé, J., Benabarre, A. Mov. Disord. (2004) [Pubmed]
  5. Effect of intramuscular clebopride on postoperative nausea and vomiting. Duarte, D.F., Linhares, S., Gesser, N., Pederneiras, S.G. Clinical therapeutics. (1985) [Pubmed]
  6. Influence of long-term treatment of the rat with clebopride on the morphology of the mammary gland. de Lima, T.C., Morato, G.S., Loch, S., Tames, D.R. Pharmacology (1990) [Pubmed]
  7. Clebopride enhances contractility of the guinea pig stomach by blocking peripheral D2 dopamine receptor and alpha-2 adrenoceptor. Takeda, K., Taniyama, K., Kuno, T., Sano, I., Ishikawa, T., Ohmura, I., Tanaka, C. J. Pharmacol. Exp. Ther. (1991) [Pubmed]
  8. The interaction of substituted benzamides with brain benzodiazepine binding sites in vitro. Horton, R.W., Lowther, S., Chivers, J., Jenner, P., Marsden, C.D., Testa, B. Br. J. Pharmacol. (1988) [Pubmed]
  9. An analysis of the hypothalamic sites at which substituted benzamide drugs act to facilitate gastric emptying in the guinea-pig. Costall, B., Gunning, S.J., Naylor, R.J. Neuropharmacology (1985) [Pubmed]
  10. Stimulatory effect of clebopride on human prolactin secretion. Perez-Lopez, F.R., Legido, A., Sisskin, M., Abos, M.D. Fertil. Steril. (1980) [Pubmed]
  11. Treatment of reflux gastritis: double blind comparison between clebopride and domperidone. A preliminary report. Angelini, G., Castagnini, A., Rizzoli, R., Pasini, A.F., Lavarini, E., Brocco, G., Scuro, L.A. The Italian journal of gastroenterology. (1990) [Pubmed]
  12. Clinical efficacy and safety of cisapride and clebopride in the management of chronic functional dyspepsia: a double-blind, randomized study. Sabbatini, F., Minieri, M., Manzi, G., Piai, G., D'Angelo, V., Mazzacca, G. The Italian journal of gastroenterology. (1991) [Pubmed]
  13. The pharmacokinetics of a new benzamide drug clebopride, in the rat and the dog. Segura, J., García, I., Borja, L., Tarrús, E., Bakke, O.M. J. Pharm. Pharmacol. (1981) [Pubmed]
  14. Metabolism of clebopride in vitro. Mass spectrometry and identification of products of amide hydrolysis and N-debenzylation. Huizing, G., Beckett, A.H., Segura, J., Bakke, O.M. Xenobiotica (1980) [Pubmed]
  15. Effect of clebopride, antidopaminergic gastrointestinal prokinetics, on cardiac repolarization. Kim, K.S., Shin, W.H., Park, S.J., Kim, E.J. Int. J. Toxicol. (2007) [Pubmed]
  16. PLS-based quantitative structure-activity relationship for substituted benzamides of clebopride type. Application of experimental design in drug design. Norinder, U., Högberg, T. Acta Chem. Scand. (1992) [Pubmed]
  17. The effect of clebopride-simethicone combination therapy on echographic visualization of retrogastric organs. Herrerías Gutiérrez, J.M., García Montes, J. Clinical therapeutics. (1994) [Pubmed]
  18. Definition of the in-vivo binding of [3H]spiperone in rat brain using substituted benzamide drugs. Chivers, J.K., Reavill, C., Jenner, P., Marsden, C.D. J. Pharm. Pharmacol. (1989) [Pubmed]
  19. Effect of clebopride on lower esophageal sphincter pressure. Ribeiro, V., da Silva, A.L., Castro, L.d.e. .P. Arquivos de gastroenterologia. (1981) [Pubmed]
  20. A central site of action for benzamide facilitation of gastric emptying. Costall, B., Gunning, S.J., Naylor, R.J., Simpson, K.H. Eur. J. Pharmacol. (1983) [Pubmed]
  21. A comparative study on the effects of domperidone, metoclopramide, clebopride and trimebutine on the gastro-duodenal preparation of the guinea pig. Schuurkes, J.A., Helsen, L.F., Van Nueten, J.M. Jpn. J. Pharmacol. (1985) [Pubmed]
  22. Potent lipophilic substituted benzamide drugs are not selective D-1 dopamine receptor antagonists in the rat. Fleminger, S., van de Waterbeemd, H., Rupniak, N.M., Reavill, C., Testa, B., Jenner, P., Marsden, C.D. J. Pharm. Pharmacol. (1983) [Pubmed]
  23. The role of multiple dopamine receptors in apomorphine and N-n-propylnorapomorphine-induced climbing and hypothermia. Moore, N.A., Axton, M.S. Eur. J. Pharmacol. (1990) [Pubmed]
  24. Potentiation of the gastric antisecretory activity of histamine H2-receptor antagonists by clebopride. Fernández, A.G., Massingham, R., Roberts, D.J. Methods and findings in experimental and clinical pharmacology. (1988) [Pubmed]
  25. Dopaminergic modulation of striatal acetylcholine release in rats depleted of dopamine as neonates. Johnson, B.J., Bruno, J.P. Neuropharmacology (1995) [Pubmed]
  26. Etiological and therapeutical observations in a case of belly dancer's dyskinesia. Linazasoro, G., Van Blercom, N., Lasa, A., Fernández, J.M., Aranzábal, I. Mov. Disord. (2005) [Pubmed]
  27. Radioimmunoassay for clebopride, a new benzamide drug with antidopaminergic activity. Yano, M., Nakamichi, K., Yamaki, T., Fukami, T., Ishikawa, K., Matsumoto, I. Chem. Pharm. Bull. (1984) [Pubmed]
  28. Antinociceptive effects of clebopride in the mouse. Bittencourt, S.C., De Lima, T.C., Morato, G.S. Gen. Pharmacol. (1995) [Pubmed]
WikiGenes - Universities